Description

Camurus: Initiation of Coverage- Regulatory Wins, Pipeline Momentum, & Market Conquest in One Package! 

Camurus AB reported significant financial performance and advancements in its pharmaceutical endeavors in the first quarter of 2025. As a leader in opioid dependence treatment, Camurus increased its foothold in key markets. The company’s flagship product, Buvidal, continued to show robust sales growth across Europe and Australia, increasing by around 6% year-over-year at constant exchange rates. However, Camurus faced mixed results in the U.S., with Brixadi royalties rising by 185% compared to the previous year but maintaining stable figures from the last quarter due to the struggling U.S. buprenorphine market, which experienced a 13% decline during the same period.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!